BackSirona Biochem Overview
Sirona Biochem Corp.

Sirona Biochem Return on Equity

Sirona Biochem (SRBCF) has a ROE of 76.97%, above the Healthcare sector average of 13.1%.

Get informed when a big investor buys or sells

+ Follow

ROE

76.97%

Return on Equity

76.97%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Sirona Biochem (SRBCF) FAQ

Sirona Biochem (SRBCF) currently reports a ROE of 76.97%. That is above the Healthcare sector average of 13.1%. Use the charts on this page to explore Sirona Biochem's ROE history and peer comparisons.

Sirona Biochem's ROE of 76.97% is higher than the Healthcare sector average of 13.1%. That is roughly 487.4% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Sirona Biochem's current 76.97% should be judged against Healthcare norms (sector average: 13.1%) and against SRBCF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 76.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.1%. From there, open related valuation or income-statement pages for Sirona Biochem, and consider following SRBCF for alerts when major investors trade the stock.

Sirona Biochem is classified in the Healthcare sector. On ROE, it currently shows 76.97% versus a sector average near 13.1%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SRBCF with unrelated industries.